PMP PEng - Oncolytics Biotech Vice Development
| ONCY Stock | USD 0.98 0.02 2.00% |
Executive
PMP PEng is Vice Development of Oncolytics Biotech
| Address | 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5 |
| Phone | 403 670 7377 |
| Web | https://www.oncolyticsbiotech.com |
Oncolytics Biotech Management Efficiency
The company has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3822) %, meaning that it created substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.75 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Oncolytics Biotech's Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 32 M in 2024, whereas Total Assets are likely to drop slightly above 30.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Ege | Seres Therapeutics | 49 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Meg Dodge | Krystal Biotech | N/A | |
| Ulrike MD | CureVac NV | 51 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Roman Necina | Hookipa Pharma | 56 | |
| Stephane Paquette | Krystal Biotech | N/A | |
| MS MD | DiaMedica Therapeutics | 51 | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Kathryn Romano | Krystal Biotech | 42 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Laurent Goux | Krystal Biotech | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Ann Hanly | Vir Biotechnology | 54 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
Management Performance
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 |
Oncolytics Biotech Leadership Team
Elected by the shareholders, the Oncolytics Biotech's board of directors comprises two types of representatives: Oncolytics Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncolytics. The board's role is to monitor Oncolytics Biotech's management team and ensure that shareholders' interests are well served. Oncolytics Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncolytics Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy Levin, Vice Operations | ||
| FCA FCA, Consultant | ||
| Dr MBA, CEO President | ||
| Jon Patton, Director Communication | ||
| FACP FACP, Consultant | ||
| Wayne MBA, Interim Board | ||
| Andrew Guttadauro, Global Inc | ||
| CA CA, Chief Officer | ||
| RN BSN, Vice Operations | ||
| PMP PEng, Vice Development | ||
| Grey Wilkinson, Scientist Medicine | ||
| BBA CM, Consultant | ||
| BBA FCA, Consultant |
Oncolytics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncolytics Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 64.03 M | ||||
| Shares Outstanding | 77.07 M | ||||
| Shares Owned By Insiders | 3.81 % | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 11.86 X | ||||
| EBITDA | (33.71 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.